Head of the class

It's increasingly clear that buysiders expect nothing but stellar numbers for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD). The stock barely moved last week despite the biotech posting 2Q14 Sovaldi sales that blew away the Street's estimates.